X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Torrent Pharma with Aventis Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TORRENT PHARMA vs SANOFI INDIA - Comparison Results

TORRENT PHARMA    Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

SANOFI INDIA 
   Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    TORRENT PHARMA SANOFI INDIA TORRENT PHARMA/
SANOFI INDIA
 
P/E (TTM) x 29.1 32.5 89.7% View Chart
P/BV x 5.5 6.2 89.6% View Chart
Dividend Yield % 1.0 1.5 67.4%  

Financials

 TORRENT PHARMA   SANOFI INDIA
EQUITY SHARE DATA
    TORRENT PHARMA
Mar-17
SANOFI INDIA
Dec-16
TORRENT PHARMA/
SANOFI INDIA
5-Yr Chart
Click to enlarge
High Rs1,7684,560 38.8%   
Low Rs1,1864,400 26.9%   
Sales per share (Unadj.) Rs346.11,028.5 33.7%  
Earnings per share (Unadj.) Rs55.2129.0 42.8%  
Cash flow per share (Unadj.) Rs73.3186.0 39.4%  
Dividends per share (Unadj.) Rs14.0068.00 20.6%  
Dividend yield (eoy) %0.91.5 62.5%  
Book value per share (Unadj.) Rs257.1753.6 34.1%  
Shares outstanding (eoy) m169.2223.03 734.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.34.4 97.9%   
Avg P/E ratio x26.834.7 77.1%  
P/CF ratio (eoy) x20.124.1 83.6%  
Price / Book Value ratio x5.75.9 96.6%  
Dividend payout %25.452.7 48.1%   
Avg Mkt Cap Rs m249,887103,174 242.2%   
No. of employees `00011.83.6 325.2%   
Total wages/salary Rs m9,9343,592 276.6%   
Avg. sales/employee Rs Th4,971.56,537.7 76.0%   
Avg. wages/employee Rs Th843.2991.4 85.1%   
Avg. net profit/employee Rs Th792.4819.8 96.7%   
INCOME DATA
Net Sales Rs m58,56923,686 247.3%  
Other income Rs m2,233708 315.4%   
Total revenues Rs m60,80224,394 249.3%   
Gross profit Rs m13,7735,281 260.8%  
Depreciation Rs m3,0691,313 233.8%   
Interest Rs m2,05615 13,704.0%   
Profit before tax Rs m10,8814,661 233.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,5451,691 91.4%   
Profit after tax Rs m9,3362,970 314.3%  
Gross profit margin %23.522.3 105.5%  
Effective tax rate %14.236.3 39.1%   
Net profit margin %15.912.5 127.1%  
BALANCE SHEET DATA
Current assets Rs m53,84115,673 343.5%   
Current liabilities Rs m31,6126,678 473.4%   
Net working cap to sales %38.038.0 99.9%  
Current ratio x1.72.3 72.6%  
Inventory Days Days9776 127.9%  
Debtors Days Days8422 375.4%  
Net fixed assets Rs m42,0798,098 519.6%   
Share capital Rs m846230 367.4%   
"Free" reserves Rs m42,65517,088 249.6%   
Net worth Rs m43,50117,356 250.6%   
Long term debt Rs m22,4080-   
Total assets Rs m101,25025,400 398.6%  
Interest coverage x6.3311.7 2.0%   
Debt to equity ratio x0.50-  
Sales to assets ratio x0.60.9 62.0%   
Return on assets %11.311.8 95.7%  
Return on equity %21.517.1 125.4%  
Return on capital %19.626.9 72.9%  
Exports to sales %024.5 0.0%   
Imports to sales %028.0 0.0%   
Exports (fob) Rs mNA5,801 0.0%   
Imports (cif) Rs mNA6,627 0.0%   
Fx inflow Rs m20,0667,145 280.8%   
Fx outflow Rs m5,3046,846 77.5%   
Net fx Rs m14,762299 4,937.2%   
CASH FLOW
From Operations Rs m10,1273,226 313.9%  
From Investments Rs m-7,869-1,555 506.1%  
From Financial Activity Rs m-1,918-1,818 105.5%  
Net Cashflow Rs m212-147 -143.9%  

Share Holding

Indian Promoters % 71.5 0.0 -  
Foreign collaborators % 0.0 60.4 -  
Indian inst/Mut Fund % 7.0 14.4 48.8%  
FIIs % 12.6 14.6 86.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.8 10.5 83.8%  
Shareholders   26,511 15,184 174.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare TORRENT PHARMA With:   FULFORD INDIA  SUVEN LIFE  CIPLA  WOCKHARDT LTD.  VENUS REMEDIES  

Compare TORRENT PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Near Record High; Realty Stocks Bleed(Closing)

After opening the day on a strong note, share markets in India witnessed volatility during the last hour of trading session. However, they managed to end the day on a positive note.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

The ONLY Thing You Need to Know About Bitcoin(The 5 Minute Wrapup)

Jan 6, 2018

You either want it or you want to get as far away from it as possible - but Bitcoin is just the noise masking the REAL opportunity. Read about it here...

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TORRENT PHARMA SHARE PRICE


Jan 18, 2018 (Close)

TRACK TORRENT PHARMA

  • Track your investment in TORRENT PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TORRENT PHARMA

TORRENT PHARMA 5-YR ANALYSIS

COMPARE TORRENT PHARMA WITH

MARKET STATS